Use and abuse of human growth hormone

E. Kirk Neely, Ronald (Ron) Rosenfeld

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Recombinant human growth hormone (hGH) has been available for nearly a decade. Side effects are rare. Its efficacy in promoting growth acceleration has been widely confirmed in children with GH deficiency (GHD), Turner syndrome, idiopathic short stature, chronic renal failure, and a variety of other conditions. The dramatic increase in height velocity in the first year of therapy partially attenuates in subsequent years in all patient groups, and convincing final height data are only available in GHD and Turner syndrome. Pediatric endocrinologists continue to be troubled by definitions of GHD. Although profound GHD is relatively obvious, other patients with severe growth failure but borderline or normal endocrine testing also respond to hGH therapy. Thus many endocrinologists use auxologic criteria [e.g. low growth velocity, height <-3 standard deviation (SD), poor predicted adult height] as the de facto basis for therapy, leading to a blurred distinction between treatment of disease and enhancement of normal characteristics and, finally, raising questions about the ultimate benefit of hGH therapy. Brief clinical trials of hGH therapy in adults both with and without GHD have reported increased muscle mass decreased fat and improvement in quality of life. Internists may soon be faced with treatment decisions analogous to these confronting pediatricians, i.e. whether to use hGH to repair aspects of the normal aging process.

Original languageEnglish (US)
Pages (from-to)407-420
Number of pages14
JournalAnnual Review of Medicine
Volume45
DOIs
StatePublished - 1994
Externally publishedYes

Fingerprint

Human Growth Hormone
Turner Syndrome
Therapeutics
Pediatrics
Growth
Muscle
Repair
Aging of materials
Fats
Growth Hormone
Chronic Kidney Failure
Testing
Quality of Life
Clinical Trials
Muscles

Keywords

  • hypopituitarism
  • medical ethics
  • short stature
  • Turner syndrome

ASJC Scopus subject areas

  • Cell Biology
  • Medicine(all)

Cite this

Use and abuse of human growth hormone. / Neely, E. Kirk; Rosenfeld, Ronald (Ron).

In: Annual Review of Medicine, Vol. 45, 1994, p. 407-420.

Research output: Contribution to journalArticle

Neely, E. Kirk ; Rosenfeld, Ronald (Ron). / Use and abuse of human growth hormone. In: Annual Review of Medicine. 1994 ; Vol. 45. pp. 407-420.
@article{5cc9133b72454eaa8e8c200cff605abe,
title = "Use and abuse of human growth hormone",
abstract = "Recombinant human growth hormone (hGH) has been available for nearly a decade. Side effects are rare. Its efficacy in promoting growth acceleration has been widely confirmed in children with GH deficiency (GHD), Turner syndrome, idiopathic short stature, chronic renal failure, and a variety of other conditions. The dramatic increase in height velocity in the first year of therapy partially attenuates in subsequent years in all patient groups, and convincing final height data are only available in GHD and Turner syndrome. Pediatric endocrinologists continue to be troubled by definitions of GHD. Although profound GHD is relatively obvious, other patients with severe growth failure but borderline or normal endocrine testing also respond to hGH therapy. Thus many endocrinologists use auxologic criteria [e.g. low growth velocity, height <-3 standard deviation (SD), poor predicted adult height] as the de facto basis for therapy, leading to a blurred distinction between treatment of disease and enhancement of normal characteristics and, finally, raising questions about the ultimate benefit of hGH therapy. Brief clinical trials of hGH therapy in adults both with and without GHD have reported increased muscle mass decreased fat and improvement in quality of life. Internists may soon be faced with treatment decisions analogous to these confronting pediatricians, i.e. whether to use hGH to repair aspects of the normal aging process.",
keywords = "hypopituitarism, medical ethics, short stature, Turner syndrome",
author = "Neely, {E. Kirk} and Rosenfeld, {Ronald (Ron)}",
year = "1994",
doi = "10.1146/annurev.med.45.1.407",
language = "English (US)",
volume = "45",
pages = "407--420",
journal = "Annual Review of Medicine",
issn = "0066-4219",
publisher = "Annual Reviews Inc.",

}

TY - JOUR

T1 - Use and abuse of human growth hormone

AU - Neely, E. Kirk

AU - Rosenfeld, Ronald (Ron)

PY - 1994

Y1 - 1994

N2 - Recombinant human growth hormone (hGH) has been available for nearly a decade. Side effects are rare. Its efficacy in promoting growth acceleration has been widely confirmed in children with GH deficiency (GHD), Turner syndrome, idiopathic short stature, chronic renal failure, and a variety of other conditions. The dramatic increase in height velocity in the first year of therapy partially attenuates in subsequent years in all patient groups, and convincing final height data are only available in GHD and Turner syndrome. Pediatric endocrinologists continue to be troubled by definitions of GHD. Although profound GHD is relatively obvious, other patients with severe growth failure but borderline or normal endocrine testing also respond to hGH therapy. Thus many endocrinologists use auxologic criteria [e.g. low growth velocity, height <-3 standard deviation (SD), poor predicted adult height] as the de facto basis for therapy, leading to a blurred distinction between treatment of disease and enhancement of normal characteristics and, finally, raising questions about the ultimate benefit of hGH therapy. Brief clinical trials of hGH therapy in adults both with and without GHD have reported increased muscle mass decreased fat and improvement in quality of life. Internists may soon be faced with treatment decisions analogous to these confronting pediatricians, i.e. whether to use hGH to repair aspects of the normal aging process.

AB - Recombinant human growth hormone (hGH) has been available for nearly a decade. Side effects are rare. Its efficacy in promoting growth acceleration has been widely confirmed in children with GH deficiency (GHD), Turner syndrome, idiopathic short stature, chronic renal failure, and a variety of other conditions. The dramatic increase in height velocity in the first year of therapy partially attenuates in subsequent years in all patient groups, and convincing final height data are only available in GHD and Turner syndrome. Pediatric endocrinologists continue to be troubled by definitions of GHD. Although profound GHD is relatively obvious, other patients with severe growth failure but borderline or normal endocrine testing also respond to hGH therapy. Thus many endocrinologists use auxologic criteria [e.g. low growth velocity, height <-3 standard deviation (SD), poor predicted adult height] as the de facto basis for therapy, leading to a blurred distinction between treatment of disease and enhancement of normal characteristics and, finally, raising questions about the ultimate benefit of hGH therapy. Brief clinical trials of hGH therapy in adults both with and without GHD have reported increased muscle mass decreased fat and improvement in quality of life. Internists may soon be faced with treatment decisions analogous to these confronting pediatricians, i.e. whether to use hGH to repair aspects of the normal aging process.

KW - hypopituitarism

KW - medical ethics

KW - short stature

KW - Turner syndrome

UR - http://www.scopus.com/inward/record.url?scp=0028239917&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028239917&partnerID=8YFLogxK

U2 - 10.1146/annurev.med.45.1.407

DO - 10.1146/annurev.med.45.1.407

M3 - Article

C2 - 8198391

AN - SCOPUS:0028239917

VL - 45

SP - 407

EP - 420

JO - Annual Review of Medicine

JF - Annual Review of Medicine

SN - 0066-4219

ER -